51
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Müller-Holzner E, Fiegl H, Marth C, Altevogt P, Zeimet AG. Molekulare Grundlage und Funktion der EGF-E2F3a Achse in der Tumorbiologie des Ovarialkarzinoms. Geburtshilfe Frauenheilkd 2010. [DOI: 10.1055/s-0030-1252096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
52
|
Steppan I, Reimer D, Müller-Holzner E, Marth C, Aigner F, Frauscher F, Frede T, Zeimet AG. Breast cancer in women: evaluation of benign and malignant axillary lymph nodes with contrast-enhanced ultrasound. ULTRASCHALL IN DER MEDIZIN (STUTTGART, GERMANY : 1980) 2010; 31:63-67. [PMID: 20094979 DOI: 10.1055/s-0028-1109847] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
PURPOSE We assessed the value of contrast-enhanced US for differentiating between benign and malignant axillary lymph nodes in breast cancer. MATERIALS AND METHODS A total of 120 axillary lymph nodes in 92 patients with breast cancer were studied. All patients underwent grayscale US examination, unenhanced and enhanced color and power Doppler US, and enhanced grayscale harmonic US examination. RESULTS The mean size of the 120 axillary lymph nodes was 1.5 cm (range 0.5 - 3.4 cm). Of all 120 axillary lymph nodes studied, 80 (67 %) were malignant and 40 (33 %) were benign according to pathological examination. The total number of vessels in baseline US did not increase between benign and malignant lymph nodes (3.3 +/- 2.2 vs. 5.4 +/- 4.0; p > 0.05). The total number of peripheral vessels was 0.5 +/- 0.8 for benign lymph nodes vs. 2.0 +/- 1.7 for malignant lymph nodes (p > 0.05). Enhanced US studies showed enhancement in both benign and malignant lymph nodes after contrast administration with a significantly higher degree of enhancement in malignant lymph nodes (p < 0.01). The total number of vessels was significantly higher in malignant lymph nodes after contrast administration (17.3 +/- 8.0 vs. 8.2 +/- 5.1, p < 0.01). Malignant lymph nodes demonstrated longer contrast enhancement duration compared to benign lymph nodes. CONCLUSION This preliminary data shows that contrast-enhanced US can differentiate between benign and malignant lymph nodes in breast cancer.
Collapse
|
53
|
Hofstetter G, Berger A, Fiegl H, Slade N, Zorić A, Holzer B, Schuster E, Mobus VJ, Reimer D, Daxenbichler G, Marth C, Zeimet AG, Concin N, Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 2010; 29:1997-2004. [PMID: 20101229 DOI: 10.1038/onc.2009.482] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Similar to p73, the tumor suppressor gene p53 is subject to alternative splicing. Besides p53DeltaE6 and p53beta, we identified p53zeta, p53delta and p53varepsilon, arising from alternative splicing of exon 6 and intron 9, respectively. p53 splice variants were present in 18 of 34 ovarian cancer cell lines (52.9%) and 134 of 245 primary ovarian cancers (54.7%). p53delta expression was associated with impaired response to primary platinum-based chemotherapy (P=0.032). Also, p53delta expression constituted an independent prognostic marker for recurrence-free and overall survival (hazard ratio 1.854, 95% confidence interval 1.121-3.065, P=0.016; and hazard ratio 1.937, 95% confidence interval 1.177-3.186, P=0.009, respectively). p53beta expression was associated with adverse clinicopathologic markers, that is, serous and poorly differentiated cancers (P=0.002 and P=0.008, respectively), and correlated with worse recurrence-free survival in patients exhibiting functionally active p53 (P=0.049). DeltaN'p73 constituted the main N-terminally truncated p73 isoform and was preferentially found in ovarian cancer cell lines showing functionally active p53, supporting our hypothesis that N-terminally truncated p73 isoforms can alleviate the selection pressure for p53 mutations by the inhibition of p53 protein function.
Collapse
|
54
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG. Die Bedeutung von E2F3a in der EGFR vermittelten Proliferation im Ovarialkarzinom – Biologische und klinische Relevanz. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1239005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
55
|
Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Mueller-Holzner E, Marth C, Altevogt P, Zeimet AG. Regulation of the EGFR-E2F3a axis by the interferon regulatory factor (IRFs) and by promoter methylation of miR-34a in ovarian cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16522 Background: Although, EGFR targeting has reached “bedside” in various tumor entities, including ovarian cancer, the essential role of E2F3a in EGFR mediated proliferation remained uncovered. Recently, we outlined the clinical relevance of E2F3a in ovarian cancer. Now we were able to elucidate the pathway between EGFR activation and E2F3a induction. Methods: Promoter mapping of E2F family members was assessed using the JASPER software. E2F3a protein was assessed by immunoblot analyses in siRNA based IRF-1, IRF-2 knockdown HOC-7 cells. Cell growth was determined by MTT assays after siRNA based knockdown of E2F3a. Expression of E2F3a regulating miR-34a, miR-210 and miR-20a were assessed by RT-PCR in 130 ovarian cancer patients and methylation status of the E2F3a promoter and of miRNA promoters were estimated using Methyllight. 6p22 amplification status of patients was determined by FISH analyses. Results: Promoter mapping of E2F family members revealed that IRF-1 and IRF-2 are potential intermediate components of the herein described EGFR-E2F3a axis. As evidenced by knock-down of IRF-1, IRF-2 or both, the ratio between the two mutually antagonistic IRF-1 and IRF-2 was found to be substantial for EGF induced E2F3a up-regulation. E2F3a knock-down yielded a complete abolishment of EGF induced cancer cell proliferation. Although, activated EGFR status showed a highly significant correlation with E2F3a expression, a subgroup of patients presented high E2F3a mRNA levels without EGFR activation. Within this subgroup promoter methylation of miRNA-34a, that regulates E2F3a, was revealed to represent an alternative mechanism of E2F3a regulation in ovarian cancer, whereas promoter methylation of E2F3a itself was not relevant in E2F3a control. Unlike in prostate or bladder cancer 6p22 amplification was not found to be relevant for E2F3a up-regulation in ovarian cancer. Conclusions: Our present data point to the substantial role of the ratio between IRF-1 and IRF-2 in EGFR mediated E2F3a induction. Furthermore, in vivo regulation of E2F3a involves methylation and thereby silencing of miR-34a. Targeting of the herein described molecular pathway, downstream EGFR, could represent an appealing therapeutic approach in ovarian cancer. No significant financial relationships to disclose.
Collapse
|
56
|
Seeber J, Sepp N, Spizzo G, Wiesbauer P, Reimer D, Marth C, Zeimet AG. Pure multivisceral manifestation of paraneoplastic dermatomyositis mimicked highly disseminated recurrent carcinoma of the fallopian tube. J Eur Acad Dermatol Venereol 2008; 22:756-7. [DOI: 10.1111/j.1468-3083.2007.02462.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
57
|
Braun S, Zeimet AG, Hefler L, Weissenboeck E, Kickmaier S, Volgger B, Reinthaller A, Marth C. Feasibility and toxicity of intraperitoneal cisplatin-paclitaxel chemotherapy (IPC) for epithelial ovarian cancer (EOC) in a routine clinical setting. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
58
|
Åvall-Lundqvist E, Wimberger P, Gladieff L, Gebski V, Huober JB, Floquet A, Fitzharris B, Zeimet AG, Heywood M, Schmalfeldt B. Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5565] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
59
|
Reimer DU, Hubalek M, Wiedmair A, Porto V, Auer D, Mueller-Holzner E, Marth C, Zeimet AG. Clinical relevance of a novel EGF pathway directly linked to E2F3a in ovarian cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
60
|
Steppan I, Sevelda U, Reimer D, Marth C, Zeimet AG. Evaluierung der Rezidivtherapie des Ovarialkarzinoms mittels pegyliertem liposomalen Doxorubicin (Caelyx®). Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
61
|
Klotz R, Zeimet AG, Reimer D, Müller-Holzner E, Chamson M, Marth C. Ist der immunhistochemische Nachweis von P38-MAP-Kinase ein prädiktiver Marker für das Ansprechen einer Gemcitabine-Therapie beim Ovarialkarzinom? Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
62
|
Reimer D, Wiedemair A, Hubalek M, Auer D, Marth C, Zeimet AG. Unterschiedliche Regulation der Isoformen E2F3a und E2F3b durch EGF im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
63
|
Auer D, Reimer D, Porto V, Wiedemair A, Marth C, Müller-Holzner E, Daxenbichler G, Zeimet AG. Coxsackie Adenovirus Rezeptor (CAR) Expression und Östrogensensitivität des Mammakarzinoms. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
64
|
Steppan I, Reimer D, Müller-Holzner E, Marth C, Zeimet AG, Aigner F, Mitterberger M, Gradl J, Pallwein L, Frauscher F. Evaluation von benignen und malignen axillären Lymphknoten mittels Kontrastmittel Ultraschall mit Tissue-Harmonic-Imaging-Modus (THI). Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
65
|
Abdel-Azim S, Jerabek-Klestil S, Müller-Holzner E, Marth C, Fogel M, Zeimet AG. Die Gewebsexpression von L1 (CD 171) als außergewöhnlicher Prädiktor für den Krankheitsverlauf des frühen Endometriumkarzinoms. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
66
|
Hofstetter G, Schuster E, Berger A, Seeber J, Wolf A, Reimer D, Daxenbichler G, Müller-Holzner E, Reinthaller A, Marth C, Zeimet AG, Zeillinger R, Concin N. P53 Isoformen Deregulierung im Ovarialkarzinom – klinische Relevanz. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
67
|
Weissenböck E, Zeimet AG, Hefler L, Kickmair S, Volgger B, Reinthaller A, Marth C, Braun S. Durchführbarkeit und Toxizität intraperitonealer Cisplatin-Paclitaxel Chemotherapie in der Behandlung des Ovarialkarzinoms: erste Daten des „Österreichischen Registers Intraperitoneale Chemotherapie“ (AGO-16-Studie). Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
68
|
Weinzierl A, Oberaigner W, Zeimet AG, Strobl I, Ramoni A, Marth C. Unterschiede im geburtshilflichen Management und neonatalem Outcome, abhängig von der Geburtszeit. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-2008-1078315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
69
|
Seeber J, Reimer D, Müller-Holzner E, Spizzo G, Sepp N, Wiesbauer P, Marth C, Zeimet AG. Fallopian tube cancer associated with paraneoplastic dermatomyositis -- asymptomatic multivisceral exacerbated dermatomyositis mimicking recurrent widespread malignant disease: case report. EUR J GYNAECOL ONCOL 2008; 29:168-170. [PMID: 18459555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
OBJECTIVE To report an uncommon case of a recurrent episode of primarily paraneoplastic dermatomyositis which was completely disconnected from the initially triggering malignancy and manifested as a silent pure multivisceral exacerbation. CASE A 70-year-old woman presented with a pure multivisceral episode of dermatomyositis without characteristic musculo-cutaneous symptoms one year after successful treatment of fallopian tube carcinoma with complete resolvement of a concomittant paraneoplastic dermatomyositis. The uncommon manifestation of recurrent dermatomyositis involving the lungs, spleen and liver, both adrenal glands and abdominal lymph nodes, mimicked a highly disseminated recurrence of the fallopian tube cancer. Physicians participating in the interdisciplinary tumor board were misled to opt for reinductive chemotherapy. Only histologic diagnosis obtained from multiple biopsies uncovered the inflammatory nature of the disease and spared the patient unneeded chemotherapy. CONCLUSION Asymptomatic multivisceral dermatomyositis may mimic metastatic spread of the initially underlying malignancy and may misdirect therapeutic strategies towards inadequate antineoplastic treatment.
Collapse
|
70
|
Reimer D, Sztankay A, Steppan I, Abfalter E, Lunzer H, Marth C, Zeimet AG. Cervical cancer associated with genital prolapse--a brief review of the literature and long-term results of successful treatment with radiochemotherapy and surgery in a very frail patient. EUR J GYNAECOL ONCOL 2008; 29:272-275. [PMID: 18592794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND A case of cervical cancer associated with irreducible procidentia successfully treated with external beam radiation and extracorporeal HDR-AL with concomitant chemotherapy followed by obliterative vaginal surgery is reported for the first time. CASE A 73-year-old woman presented in frail condition suffering from a huge, irreducible uterovaginal procidentia combined with a squamous cell carcinoma of the cervix in FIGO Stage IIa. Successful treatment consisted of sequential application of combined radiotherapy with concurrent cisplatin chemotherapy followed by total vaginal hysterectomy and partial colpectomy with colpocleisis according to the Labhardt method. The five-year follow-up documents the excellent long-term results with regard to cervical cancer and pelvic floor stability. CONCLUSION Especially in patients ineligible for extended surgery, radiochemotherapy followed by an obliterative surgical approach is feasible without aberrant wound healing and constitutes a suitable and efficient option for treating carcinomas of the cervix associated with irreducible genital prolapse.
Collapse
|
71
|
Reimer D, Steppan I, Wiedemair A, Auer D, Marth C, Zeimet AG. Die klinische Bedeutung der löslichen Splicevarianten des Coxsackie Adenovirus Rezeptors (CAR) im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-983447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
72
|
Hubalek M, Fessler S, Zeimet AG, Brezinka C, Mueller-Holzner E, Marth C. Chemotherapeutische Behandlung eines Dysgerminoms in der Schwangerschaft. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-983546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
73
|
Reimer D, Steppan I, Wiedemair A, Fleischer M, Marth C, Zeimet AG. Die Rolle der E2F3 Isoformen in der EGF vermittelten Proliferation beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-983542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
74
|
Weissenböck E, Zeimet AG, Marth C, Braun S. Erste klinische Erfahrungen mit intraperitonealer Cisplatin-Paclitaxel-Chemotherapie (IPC) beim epithelialen Ovarialkarzinom (EOC). Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-983528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
75
|
Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Volgger B, Stempfl A, Marth C. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 2006; 102:226-9. [PMID: 16443259 DOI: 10.1016/j.ygyno.2005.12.017] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2005] [Revised: 11/28/2005] [Accepted: 12/01/2005] [Indexed: 12/30/2022]
Abstract
OBJECTIVES Platinum resistance is a significant problem in patients with ovarian cancer. The aim of this phase II study was to define the response rates, the progression-free survival and the toxicity profile of the combination of PEG liposomal doxorubicin (L-DXR) and gemcitabine (GEM). MATERIAL AND METHODS Thirty one patients with histologically confirmed platinum-refractory or -resistant epithelial ovarian cancer were scheduled to receive 6 cycles of L-DXR 30 mg/m(2) on day 1 as well as GEM 650 mg/m(2) on days 1 and 8 every 28 days. RESULTS The median number of chemotherapy cycles given was 4. The mean dose intensity for L-DXR and GEM on day 1 was 96% and 97%, respectively. The mean dose intensity for GEM on day 8 was 93%. The overall response rate was 33% (10 of 30 evaluable patients; 20% complete responses). The median progression-free survival was 3.8 months, and the median overall survival was 15.8 months, respectively. Toxicity was acceptable. One quarter of patients developed grade 3 or 4 neutropenia, but none developed febrile neutropenia. Palmoplantar erythrodysesthesia (PPE) grades 2 and 3 occurred in 13% and 3% only, respectively, and no grade 4 PPE was observed. Grades 1 to 3 stomatitis was found in 58% of patients (10% grade 3). CONCLUSION The combination of L-DXR and GEM is an active and acceptably tolerated option in the treatment of patients with platinum-resistant and -refractory ovarian cancer. Dose reductions seem advisable in the case of > or =grade 2 stomatitis and/or PPE > or =grade 2.
Collapse
|